{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:08:39Z","timestamp":1770419319097,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To analyze the epidemiology, clinical features and costs of hospitalized patients with gout during the last decade in Spain. Retrospective observational study based on data from the Minimum Basic Data Set (MBDS) from the Spanish National Health Service database. Patients\u2009\u2265\u200918\u00a0years with any gout diagnosis at discharge who had been admitted to public or private hospitals between 2005 and 2015 were included. Patients were divided in two periods: p1 (2005\u20132010) and p2 (2011\u20132015) to compare the number of hospitalizations, mean costs and mortality rates. Data from 192,037 patients with gout was analyzed. There was an increase in the number of hospitalized patients with gout (p\u2009&lt;\u20090.001). The more frequent comorbidities were diabetes (27.6% of patients), kidney disease (26.6%) and heart failure (19.3%). Liver disease (OR 2.61), dementia (OR 2.13), cerebrovascular diseases (OR 1.57), heart failure (OR 1.41), and kidney disease (OR 1.34) were associated with a higher mortality risk. Women had a lower risk of mortality than men (OR 0.85). General mortality rates in these hospitalized patients progressively increased over the years (p\u2009&lt;\u20090.001). In addition, costs gradually rose, presenting a significant increase in p2 even after adjusting for inflation (p\u2009=\u20090.001). A progressive increase in hospitalizations, mortality rates and cost in hospitalized patients with gout was observed. This harmful trend in a preventable illness highlights the need for change and the search for new healthcare strategies.<\/jats:p>","DOI":"10.1038\/s41598-021-92673-3","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T10:02:56Z","timestamp":1624528976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Healthcare-related impact of gout in hospitalized patients in Spain"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-5330","authenticated-orcid":false,"given":"Diego","family":"Benavent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Peiteado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Martinez-Huedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Hernandez-Hurtado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"92673_CR1","first-page":"925","volume":"59","author":"MD Harris","year":"1999","unstructured":"Harris, M.D., Siegel, L.B., Alloway, J.A. Gout and hyperuricemia. Am. Fam. Phys. 59, 925\u2013934 (1999).","journal-title":"Am. Fam. Phys."},{"key":"92673_CR2","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","volume":"116","author":"HK Choi","year":"2007","unstructured":"Choi, H.K., Curhan, G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 116, 894\u2013900 (2007).","journal-title":"Circulation"},{"key":"92673_CR3","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1002\/art.22014","volume":"54","author":"E Krishnan","year":"2006","unstructured":"Krishnan, E., Baker, J.F., Furst, D.E., Schumacher, H.R. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 54, 2688\u20132696 (2006).","journal-title":"Arthritis Rheum."},{"key":"92673_CR4","first-page":"104","volume":"33","author":"T Neogi","year":"2006","unstructured":"Neogi, T., Hunter, D.J., Chaisson, C.E., Allensworth-Davies, D., Zhang, Y. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J. Rheumatol. 33, 104\u2013109 (2006).","journal-title":"J. Rheumatol."},{"key":"92673_CR5","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/ard.2007.070755","volume":"66","author":"E Roddy","year":"2007","unstructured":"Roddy, E., Zhang, W., Doherty, M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann. Rheum. Dis. 66, 1311\u20131315 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"92673_CR6","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu, Y., Pandya, B.J., Choi, H.K. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007\u20132008. Arthritis Rheum. 63, 3136\u20133141 (2011).","journal-title":"Arthritis Rheum."},{"key":"92673_CR7","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/0895-4356(94)00244-K","volume":"48","author":"CM Harris","year":"1995","unstructured":"Harris, C.M., Lloyd, D.C.E.F., Lewis, J. The prevalence and prophylaxis of gout in England. J. Clin. Epidemiol. 48, 1153\u20131158 (1995).","journal-title":"J. Clin. Epidemiol."},{"key":"92673_CR8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin, M., Jacobsson, L., Roddy, E. Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors. Nat. Rev. Rheumatol. 16, 380\u2013390 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"92673_CR9","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/rheumatology\/kez196","volume":"58","author":"G Singh","year":"2019","unstructured":"Singh, G., Lingala, B., Mithal, A. Gout and hyperuricaemia in the USA: Prevalence and trends. Rheumatology (Oxford). 58, 2177\u20132180 (2019).","journal-title":"Rheumatology (Oxford)."},{"key":"92673_CR10","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1093\/rheumatology\/key390","volume":"58","author":"K Zobbe","year":"2019","unstructured":"Zobbe, K., Prieto-Alhambra, D., Cordtz, R., H\u00f8jgaard, P., Hindrup, J.S., Kristensen, L.E., Dreyer, L. Secular trends in the incidence and prevalence of gout in Denmark from 1995 to 2015: A nationwide register-based study. Rheumatology (Oxford). 58, 836\u2013839 (2019).","journal-title":"Rheumatology (Oxford)."},{"key":"92673_CR11","first-page":"u210130.w4918","volume":"6","author":"G Blakey","year":"2019","unstructured":"Blakey, G., Callear, J. Gout in primary care: Can we improve patient outcomes? Br. J. Gen. Pract. 6, u210130.w4918 (2019).","journal-title":"Br. J. Gen. Pract."},{"key":"92673_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/rheumatology\/kes253","volume":"52","author":"PC Robinson","year":"2013","unstructured":"Robinson, P.C., Merriman, T.R., Herbison, P., Highton, J. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999\u20132009. Rheumatology (United Kingdom). 52, 118\u2013126 (2013).","journal-title":"Rheumatology (United Kingdom)."},{"key":"92673_CR13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/acr.23012","volume":"69","author":"SK Rai","year":"2017","unstructured":"Rai, S.K., Avi\u00f1a-Zubieta, J.A., McCormick. N., de Vera, M.A., Lacaille, D., Sayre, E.C., et al. Trends in gout and rheumatoid arthritis hospitalizations in Canada from 2000 to 2011. Arthritis Care Res. 69, 758\u2013762 (2017).","journal-title":"Arthritis Care Res."},{"key":"92673_CR14","unstructured":"Msssi.gob.es [Internet]. Ministerio de Sanidad, Consumo y Bienestar Social, MBDS [Conjunto M\u00ednimo B\u00e1sico Datos]. https:\/\/www.msssi.gob.es\/estadEstudios\/estadisticas\/inforRecopilaciones\/anaDesarrolloGDR.htm. (2016)."},{"key":"92673_CR15","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3899\/jrheum.170806","volume":"45","author":"MM Elfishawi","year":"2018","unstructured":"Elfishawi, M.M., Zleik, N., Kvrgic, Z., Michet, C.J., Crowson, C.S., Matteson, E.L., et al. The rising incidence of gout and the increasing burden of comorbidities: A population-based study over 20 years. J. Rheumatol. 45, 574\u2013579 (2018).","journal-title":"J. Rheumatol."},{"key":"92673_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","volume":"15","author":"T Bardin","year":"2017","unstructured":"Bardin, T., Richette, P. Impact of comorbidities on gout and hyperuricaemia: An update on prevalence and treatment options. BMC Med. 15, 123 (2017).","journal-title":"BMC Med."},{"key":"92673_CR17","doi-asserted-by":"publisher","first-page":"25766","DOI":"10.1038\/srep25766","volume":"6","author":"A Pan","year":"2016","unstructured":"Pan, A., Teng, G.G., Yuan, J.M., Koh, W.P. Bidirectional association between diabetes and gout: The Singapore Chinese Health Study. Sci. Rep. 6, 25766 (2016).","journal-title":"Sci. Rep."},{"key":"92673_CR18","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.semarthrit.2020.04.008","volume":"50","author":"JA Singh","year":"2020","unstructured":"Singh, J.A., Gaffo, A. Gout epidemiology and comorbidities. Semin. Arthritis Rheum. 50, S11\u2013S16 (2020).","journal-title":"Semin. Arthritis Rheum."},{"key":"92673_CR19","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.amjcard.2004.06.032","volume":"94","author":"G Mercuro","year":"2004","unstructured":"Mercuro, G., Vitale, C., Cerquetani, E., Zoncu, S., Deidda, M., Fini, M., Rosano, G.M. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am. J. Cardiol. 94, 932\u2013935 (2004).","journal-title":"Am. J. Cardiol."},{"key":"92673_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13075-018-1746-1","volume":"20","author":"M Roughley","year":"2018","unstructured":"Roughley, M., Sultan, A.A., Clarson, L., Muller, S., Whittle, R., Belcher, J., et al. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: A population-based cohort study. Arthritis Res. Ther. 20, 243 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"92673_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13075-016-0936-y","volume":"18","author":"JA Singh","year":"2016","unstructured":"Singh, J.A., Yu, S. Gout-related inpatient utilization: A study of predictors of outcomes and time trends. Arthritis Res. Ther. 18, 57 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"92673_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11926-011-0234-2","volume":"14","author":"K Lottmann","year":"2012","unstructured":"Lottmann, K., Chen, X., Sch\u00e4dlich, P.K. Association between gout and all-cause as well as cardiovascular mortality: A systematic review. Curr. Rheumatol. Rep. 14, 195\u2013203 (2012).","journal-title":"Curr. Rheumatol. Rep."},{"key":"92673_CR23","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1097\/MJT.0b013e31820543c5","volume":"19","author":"EQ Wu","year":"2012","unstructured":"Wu, E.Q., Forsythe, A., Guerin, A., Yu, A.P., Latremouille-Viau, D., Tsaneva, M. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am. J. Ther. 19, e157\u2013166 (2012).","journal-title":"Am. J. Ther."},{"key":"92673_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1590\/S1135-57272009000500012","volume":"83","author":"I Pe\u00f1a-Rey","year":"2009","unstructured":"Pe\u00f1a-Rey, I., Mart\u00ednez de Arag\u00f3n, M.V., Villaverde Hueso, A., et al. Epidemiolog\u00eda de la varicela en Espa\u00f1a en los per\u00edodos pre y post vacunaci\u00f3n. Rev. Esp. Salud P\u00fablica 83, 711\u2013724 (2009).","journal-title":"Rev. Esp. Salud P\u00fablica"},{"key":"92673_CR25","doi-asserted-by":"publisher","first-page":"R224","DOI":"10.1186\/ar4425","volume":"15","author":"JA Singh","year":"2013","unstructured":"Singh, J.A. Veterans Affairs databases are accurate for gout-related health care utilization: A validation study. Arthritis Res. Ther. 15, R224 (2013).","journal-title":"Arthritis Res. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92673-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92673-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92673-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T10:39:39Z","timestamp":1670063979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92673-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["92673"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-92673-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]},"assertion":[{"value":"10 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DB: Speaking fees Abbvie, Roche. DP: Speaking fees from AbbVie, Roche, and MSD and Grant\/research support from AbbVie, Eli Lilly, MSD, and Roche. AB: Grant\/research support: Abbvie, Pfizer, Novartis, BMS, Nordic, Sanofi. Consultant: Abbvie, Pfizer, Novartis, BMS, Nordic, Sanofi, Sandoz, Lilly. Speakers bureau: Pfizer, Novartis, UCB, Nordic, Sanofi, Sandoz, Lilly. EDM:\u00a0Grant\/research support from: AbbVie, Novartis, Pfizer, Consultant for: AbbVie, Novartis, Pfizer, Speakers bureau: AbbVie, BMS, MSD, Novartis, Pfizer, UCB, Roche. No other disclosures relevant to this article were reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13287"}}